Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Cancers (Basel) ; 13(13)2021 Jul 04.
Article in English | MEDLINE | ID: mdl-34283070

ABSTRACT

Cancer-associated fibroblasts (CAFs) are known to increase tumor growth and to stimulate invasion and metastasis. Increasing evidence suggests that CAFs mediate response to various treatments. HNSCC cell lines were co-cultured with their patient-matched CAFs in 2D and 3D in vitro models, and the tumor cell gene expression profiles were investigated by cDNA microarray and qRT-PCR. The mRNA expression of eight candidate genes was examined in tumor biopsies from 32 HNSCC patients and in five biopsies from normal oral tissue. Differences in overall survival (OS) were tested with Kaplan-Meier long-rank analysis. Thirteen protein coding genes were found to be differentially expressed in tumor cells co-cultured with CAFs in 2D and 81 in 3D when compared to tumor cells cultured without CAFs. Six of these genes were upregulated both in 2D and 3D (POSTN, GREM1, BGN, COL1A2, COL6A3, and COL1A1). Moreover, two genes upregulated in 3D, MMP9 and FMOD, were significantly associated with the OS. In conclusion, we demonstrated in vitro that CAF-derived signals alter the tumor cell expression of multiple genes, several of which are associated with differentiation, epithelial-to-mesenchymal transition (EMT) phenotype, and metastasis. Moreover, six of the most highly upregulated genes were found to be overexpressed in tumor tissue compared to normal tissue.

2.
J Clin Med ; 9(6)2020 Jun 25.
Article in English | MEDLINE | ID: mdl-32630430

ABSTRACT

The nociceptive withdrawal reflex (NWR) is used to probe spinal cord excitability in chronic pain states. Here, we used an automated and unbiased procedure for determining the NWR threshold and compared the reflex thresholds and corresponding pain ratings in a well-characterized cohort of fibromyalgia (n = 29) and matched healthy controls (n = 21). Surface electrical stimuli were delivered to the foot in a stepwise incremental and decremental manner. The surface electromyographic activity was recorded from the ipsilateral tibialis anterior muscle. Fibromyalgia patients reported significantly higher scores for psychological distress and pain-related disability and a significantly lower score for perceived state of health compared to the matched controls. The subjective pain ratings were significantly higher in patients. The NWR thresholds were similar to the controls. In the patients, but not in controls, the NWR thresholds and subjective pain ratings were significantly correlated. Our results showed an increased subjective pain sensitivity in fibromyalgia, but we found no evidence for spinal sensitization based on the reflex measures.

3.
J Oral Pathol Med ; 46(9): 717-724, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28036101

ABSTRACT

BACKGROUND: The aims of this study were to validate in vitro drug sensitivity testing of head and neck squamous cell carcinoma (HNSCC) cell lines in an in vivo xenograft model and to identify treatment-induced changes in the epidermal growth factor receptor (EGFR) signaling pathway that could be used as markers for cetuximab treatment response. MATERIALS AND METHODS: The in vitro and in vivo cetuximab sensitivity of two HNSCC cell lines, UT-SCC-14 and UT-SCC-45, was assessed using a crystal violet assay and xenografts in nude mice, respectively. The expression of EGFR, phosphorylated EGFR (pEGFR), phosphorylated Src (pSrc), and Ki-67 was investigated by immunohistochemistry. To verify these results, the in vitro expression of EGFR and pEGFR was analyzed with ELISA in a panel of 10 HNSCC cell lines. RESULTS: A close correlation was found between in vitro and in vivo cetuximab sensitivity data in the two investigated HNSCC cell lines. In treatment sensitive UT-SCC-14 xenografts, there was a decrease in EGFR, pEGFR, and pSrc upon cetuximab treatment. Interestingly, in insensitive UT-SCC-45 xenografts, an increased expression of these three proteins was found. The change in EGFR and pEGFR expression in vivo was confirmed in cetuximab-sensitive and cetuximab-insensitive HNSCC cell lines using ELISA. CONCLUSION: High sensitivity to cetuximab was strongly associated with a treatment-induced reduction in pEGFR both in vivo and in vitro in a panel of HNSCC cell lines, suggesting that EGFR and pEGFR dynamics could be used as a predictive biomarker for cetuximab treatment response.


Subject(s)
Antineoplastic Agents, Immunological/pharmacology , Antineoplastic Agents, Immunological/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Cetuximab/pharmacology , Cetuximab/therapeutic use , ErbB Receptors/drug effects , Head and Neck Neoplasms/drug therapy , Oncogene Protein pp60(v-src)/drug effects , Animals , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Drug Screening Assays, Antitumor , ErbB Receptors/biosynthesis , Female , Head and Neck Neoplasms/metabolism , Heterografts , Humans , Mice , Mice, Inbred BALB C , Oncogene Protein pp60(v-src)/biosynthesis , Phosphorylation , Squamous Cell Carcinoma of Head and Neck
4.
J Oral Pathol Med ; 45(9): 640-646, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26757432

ABSTRACT

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) tumors are often therapy resistant and may originate from cancer stem cells or tumor cells with an epithelial-to-mesenchymal transition (EMT) phenotype. The aim of this study was to characterize HNSCC cell lines with regard to EMT profile and to investigate the influence of EMT on the response to treatment. METHODS: mRNA expression of the EMT-associated genes CDH1 (E-cadherin), CDH2 (N-cadherin), FOXC2, TWIST1, VIM (vimentin), and FN1 (fibronectin) was determined using quantitative real-time PCR. Cell morphology and migration were investigated by phase-contrast microscopy and Boyden chamber assay, respectively. The cell surface expression of CD44 and epidermal growth factor receptor (EGFR) was examined by flow cytometry. The response to radiotherapy, cetuximab, and dasatinib was assessed by crystal violet staining. RESULTS: A total of 25 cell lines investigated differed greatly with regard to EMT phenotype. Cell lines with an EMT expression profile showed a mesenchymal morphology and a high migratory capacity. In addition, they exhibited a high cell surface expression of CD44 and a low expression of EGFR, a pattern previously associated with stemness. When the EMT inducer transforming growth factor-ß (TGF-ß) was added to non-EMT cells, changes in treatment responses were observed. Moreover, the expression of TWIST1 was found to correlate with radioresistance. CONCLUSIONS: The data presented in this report suggest that EMT is associated with a CD44high /EGFRlow phenotype and possibly negative impact on radiotherapy response in HNSCC cell lines.


Subject(s)
Epithelial-Mesenchymal Transition , ErbB Receptors/metabolism , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/therapy , Hyaluronan Receptors/metabolism , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Cell Movement , Humans , Nuclear Proteins/metabolism , Phenotype , Prognosis , RNA, Messenger/metabolism , Radiotherapy , Twist-Related Protein 1/metabolism
5.
Acta Derm Venereol ; 96(4): 521-4, 2016 May.
Article in English | MEDLINE | ID: mdl-26611655

ABSTRACT

Simple, validated eczema severity scores are required for the evaluation of interventions. The Rajka & Langeland (R&L) scale is based on 3 domains (extent, course, and intensity); however, its validity is not yet confirmed. The aim of this study was to investigate the quality aspects of the R&L scale in clinical practice. In the first part of the study, experts and consumers judged the content validity of the scale. The second part of the study was performed with 87 children during a 4-month eczema school. Construct validity, internal consistency, sensitivity to change, time consumption and health-related quality of life variables were investigated. The content of the R&L scale was considered valid by 45 panellists. Inter- and intra-observer reliability was very good. Divergent construct validity was adequate, while convergent construct validity and internal consistency were inadequate. The R&L scale was able to define a significant improvement in eczema during the eczema school. The time required for completing the R&L assessment was significantly shorter than for objective Severity Scoring of Atopic Dermatitis (SCORAD). The R&L scale is a simple, fast, valid, reliable and sensitive tool for scoring of atopic dermatitis in everyday clinical practice.


Subject(s)
Eczema/diagnosis , Surveys and Questionnaires , Eczema/psychology , Eczema/therapy , Health Status , Humans , Judgment , Observer Variation , Predictive Value of Tests , Quality of Life , Remission Induction , Reproducibility of Results , Severity of Illness Index , Time Factors , Treatment Outcome
6.
J Oral Pathol Med ; 45(1): 9-16, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25677871

ABSTRACT

BACKGROUND: Head and neck squamous cell carcinoma is frequently associated with aberrant epidermal growth factor receptor (EGFR) signaling, which contributes to tumor growth. Here, the functional importance of EGFR ligands in relation to proliferation and sensitivity to the EGFR-targeted therapy cetuximab was investigated in three tongue cancer cell lines. METHODS: The influence of epidermal growth factor (EGF), amphiregulin (AR), and epiregulin (EPR) on tumor cell proliferation and cetuximab response was evaluated by the addition of recombinant human (rh) proteins or by siRNA-mediated downregulation of the endogenous ligand production. The expression, activation and cellular distribution of EGFR were assessed by Western blot analysis and immunocytochemistry. RESULTS: EGF downregulation suppressed the proliferation of all investigated tumor cell lines, whereas the response to an increased level of EGF differed between EGFR-overexpressing and EGFR-non-overexpressing cell lines. Furthermore, tumor cells consistently displayed increased cetuximab resistance upon the addition of rhEGF, whereas EGF silencing was associated with an improved cetuximab response. The data regarding AR and EPR were inconclusive. CONCLUSIONS: Our data suggest that the amount of EGF is a determinant of the tumor cell proliferation rate and the response to cetuximab treatment in tongue cancer. Thus, EGF is a potential predictive biomarker of poor cetuximab response and a possible treatment target.


Subject(s)
Biomarkers, Tumor/biosynthesis , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/metabolism , Cetuximab/pharmacology , Epidermal Growth Factor/biosynthesis , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/metabolism , Tongue Neoplasms/drug therapy , Tongue Neoplasms/metabolism , Amphiregulin/deficiency , Amphiregulin/genetics , Amphiregulin/pharmacology , Antineoplastic Agents/pharmacology , Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Down-Regulation , Drug Resistance, Neoplasm , Epidermal Growth Factor/analysis , Epiregulin/deficiency , Epiregulin/genetics , Epiregulin/pharmacology , ErbB Receptors/biosynthesis , ErbB Receptors/metabolism , Head and Neck Neoplasms/pathology , Humans , Immunohistochemistry , Ligands , Molecular Targeted Therapy , Squamous Cell Carcinoma of Head and Neck , Tongue Neoplasms/pathology
7.
Oral Oncol ; 50(9): 832-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24993889

ABSTRACT

OBJECTIVES: Targeted therapy against the epidermal growth factor receptor (EGFR) only variably represents a therapeutic advance in head and neck squamous cell carcinoma (HNSCC). This study addresses the need of biomarkers of treatment response to the EGFR-targeting antibody cetuximab (Erbitux®). MATERIALS AND METHODS: The intrinsic cetuximab sensitivity of HNSCC cell lines was assessed by a crystal violet assay. Gene copy number analysis of five resistant and five sensitive cell lines was performed using the Affymetrix SNP 6.0 platform. Quantitative real-time PCR was used for verification of selected copy number alterations and assessment of mRNA expression. The functional importance of the findings on the gene and mRNA level was investigated employing siRNA technology. The data was statistically evaluated using Mann-Whitney U-test and Spearman's correlation test. RESULTS: Analysis of the intrinsic cetuximab sensitivity of 32 HNSCC cell lines characterized five and nine lines as cetuximab sensitive or resistant, respectively. Gene copy number analysis of five resistant versus five sensitive cell lines identified 39 amplified protein-coding genes, including YAP1, in the genomic regions 11q22.1 or 5p13-15. Assessment using qPCR verified that YAP1 amplification associated with cetuximab resistance. Amplification of YAP1 correlated to higher mRNA levels, and RNA knockdown resulted in increased cetuximab sensitivity. Assessment of several independent clinical data sets in the public domain confirmed YAP1 amplifications in multiple tumor types including HNSCC, along with highly differential expression in a subset of HNSCC patients. CONCLUSION: Taken together, we provide evidence that YAP1 could represent a novel biomarker gene of cetuximab resistance in HNSCC cell lines.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Antibodies, Monoclonal, Humanized/therapeutic use , Biomarkers/metabolism , Carcinoma, Squamous Cell/metabolism , Head and Neck Neoplasms/metabolism , Phosphoproteins/metabolism , Adaptor Proteins, Signal Transducing/genetics , Base Sequence , Carcinoma, Squamous Cell/drug therapy , Cell Line, Tumor , Cetuximab , DNA Primers , Drug Resistance, Neoplasm , Gene Silencing , Head and Neck Neoplasms/drug therapy , Humans , Phosphoproteins/genetics , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Transcription Factors , YAP-Signaling Proteins
9.
J Oral Pathol Med ; 42(1): 26-36, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22643066

ABSTRACT

BACKGROUND: Combination treatment (chemoradiotherapy) is the standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC); however, treatment resistance and local recurrence are significant problems. A high level of epidermal growth factor receptor (EGFR) has been associated with a more aggressive phenotype as well as decreased responsiveness to radio- or chemotherapy. We examined the role of EGFR status and EGFR ligand expression for the treatment response. METHODS: Intrinsic sensitivity to radiotherapy, cisplatin, and cetuximab treatments was investigated in 25 HNSCC cell lines. EGFR gene copy number, mRNA and protein expression, EGFR and Akt phosphorylation status, and mRNA expression of the EGFR ligands were analyzed using quantitative PCR and ELISA and assessed for their impact on treatment sensitivity. RESULTS: Different treatment modalities yielded great diversity in outcome; of note, cetuximab treatment stimulated growth in one cell line. When treatments were combined primarily additive effects were observed. While radioresistance tended to be associated with a high level of phosphorylated EGFR (pEGFR; P = 0.09), cetuximab-resistant cells had low levels of pEGFR (P = 0.13). The three most cetuximab-sensitive cell lines had high EGFR gene copy numbers. Furthermore, cetuximab treatment response was significantly correlated with epiregulin mRNA expression (r = -0.408, P = 0.043). Cisplatin-resistant tumor cells expressed significantly lower levels of EGFR protein (P = 0.04) compared to cisplatin-sensitive cells and tended to have lower levels of phosphorylated Akt (pAkt; P = 0.13) and lower expression levels of amphiregulin (P = 0.18). CONCLUSIONS: Epidermal growth factor receptor status and ligand expression influence the treatment sensitivity of HNSCC cells and may be useful as predictive markers.


Subject(s)
Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Drug Resistance, Neoplasm , ErbB Receptors/metabolism , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Radiation Tolerance , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Cetuximab , Chemoradiotherapy , Cisplatin/therapeutic use , Epidermal Growth Factor/biosynthesis , ErbB Receptors/genetics , Gene Dosage , Head and Neck Neoplasms/metabolism , Humans , Intercellular Signaling Peptides and Proteins/biosynthesis , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Statistics, Nonparametric
10.
PLoS One ; 7(9): e44071, 2012.
Article in English | MEDLINE | ID: mdl-23049743

ABSTRACT

Mortality in head and neck squamous cell carcinoma (HNSCC) is high due to emergence of therapy resistance which results in local and regional recurrences that may have their origin in resistant cancer stem cells (CSCs) or cells with an epithelial-mesenchymal transition (EMT) phenotype. In the present study, we investigate the possibility of using the cell surface expression of CD44 and epidermal growth factor receptor (EGFR), both of which have been used as stem cell markers, to identify subpopulations within HNSCC cell lines that differ with respect to phenotype and treatment sensitivity. Three subpopulations, consisting of CD44(high)/EGFR(low), CD44(high)/EGFR(high) and CD44(low) cells, respectively, were collected by fluorescence-activated cell sorting. The CD44(high)/EGFR(low) population showed a spindle-shaped EMT-like morphology, while the CD44(low) population was dominated by cobblestone-shaped cells. The CD44(high)/EGFR(low) population was enriched with cells in G0/G1 and showed a relatively low proliferation rate and a high plating efficiency. Using a real time PCR array, 27 genes, of which 14 were related to an EMT phenotype and two with stemness, were found to be differentially expressed in CD44(high)/EGFR(low) cells in comparison to CD44(low) cells. Moreover, CD44(high)/EGFR(low) cells showed a low sensitivity to radiation, cisplatin, cetuximab and gefitinib, and a high sensitivity to dasatinib relative to its CD44(high)/EGFR(high) and CD44(low) counterparts. In conclusion, our results show that the combination of CD44 (high) and EGFR (low) cell surface expression can be used to identify a treatment resistant subpopulation with an EMT phenotype in HNSCC cell lines.


Subject(s)
Cell Lineage/genetics , Epithelial-Mesenchymal Transition/genetics , ErbB Receptors/genetics , Hyaluronan Receptors/genetics , Neoplastic Stem Cells/metabolism , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/pharmacology , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/radiotherapy , Cell Cycle/drug effects , Cell Cycle/radiation effects , Cell Line, Tumor , Cell Lineage/drug effects , Cell Lineage/radiation effects , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Cell Shape/drug effects , Cell Shape/radiation effects , Cetuximab , Cisplatin/pharmacology , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/radiation effects , Epithelial-Mesenchymal Transition/immunology , ErbB Receptors/immunology , Flow Cytometry , Gamma Rays , Gefitinib , Gene Expression/drug effects , Gene Expression/radiation effects , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/radiotherapy , Humans , Hyaluronan Receptors/immunology , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/radiation effects , Oligonucleotide Array Sequence Analysis , Organ Specificity , Quinazolines/pharmacology
11.
Ann Clin Lab Sci ; 42(3): 231-42, 2012.
Article in English | MEDLINE | ID: mdl-22964611

ABSTRACT

Bax-mediated permeabilization of the outer mitochondrial membrane and release of apoptogenic factors into the cytosol are key events that occur during apoptosis. Likewise, apoptosis is associated with permeabilization of the lysosomal membrane and release of lysosomal cathepsins into the cytosol. This report identifies proteolytically active cathepsin D as an important component of apoptotic signaling following lysosomal membrane permeabilization in fibroblasts. Lysosome-mediated cell death is associated with degradation of Bax sequestering 14-3-3 proteins, cleavage of the Bax activator Bid, and translocation of Bax to mitochondria, all of which were cathepsin D-dependent. Processing of Bid could be reproduced by enforced lysosomal membrane permeabilization, using the lysosomotropic detergent O-methyl-serine dodecylamine hydrochloride (MSDH). We identified three cathepsin D-specific cleavage sites in Bid, Phe24, Trp48, and Phe183. Cathepsin D-cleaved Bid induced Bax-mediated release of cytochrome c from purified mitochondria, indicating that the fragments generated are functionally active. Moreover, apoptosis was associated with cytosolic acidification, thereby providing a more favorable environment for the cathepsin D-mediated cleavage of Bid. Our study suggests that cytosolic cathepsin D triggers Bax-mediated cytochrome c release by proteolytic activation of Bid.


Subject(s)
Apoptosis , BH3 Interacting Domain Death Agonist Protein/metabolism , Cathepsin D/metabolism , Lysosomes/metabolism , Phenylalanine/metabolism , Protein Processing, Post-Translational , Tryptophan/metabolism , 14-3-3 Proteins/metabolism , Animals , Apoptosis/drug effects , Humans , Intracellular Membranes/drug effects , Intracellular Membranes/metabolism , Lysosomes/drug effects , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Permeability/drug effects , Protein Processing, Post-Translational/drug effects , Protein Transport/drug effects , Proteolysis/drug effects , Rats , Rats, Sprague-Dawley , Staurosporine/pharmacology , Substrate Specificity/drug effects , bcl-2-Associated X Protein/metabolism
12.
Mol Cancer Res ; 10(9): 1158-68, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22809838

ABSTRACT

A growing body of evidence suggests that components of the tumor microenvironment, including cancer-associated fibroblasts (CAF), may modulate the treatment sensitivity of tumor cells. Here, we investigated the possible influence of CAFs on the sensitivity of head and neck squamous cell carcinoma (HNSCC) cell lines to cetuximab, an antagonistic epidermal growth factor receptor (EGFR) antibody. Cetuximab treatment caused a reduction in the proliferation rate of HNSCC cell lines, whereas the growth of HNSCC-derived CAF cultures was unaffected. When tumor cells were cocultured with CAFs in a transwell system, the cetuximab-induced growth inhibition was reduced, and a complete protection from growth inhibition was observed in one of the tumor cell lines investigated. Media that had been conditioned by CAFs offered protection from cetuximab treatment in a concentration-dependent manner, suggesting that the resistance to treatment was mediated by CAF-derived soluble factors. The coculture of HNSCC cell lines with CAFs resulted in an elevated expression of matrix metalloproteinase-1 (MMP-1) in both the tumor cells and CAFs. Moreover, the CAF-induced resistance was partly abolished by the presence of an MMP inhibitor. However, CAFs treated with siRNA targeting MMP-1 still protected tumor cells from cetuximab treatment, suggesting that several MMPs may cooperate to facilitate resistance or that the protective effect is mediated by another member of the MMP family. These results identify a novel CAF-dependent modulation of cetuximab sensitivity and suggest that inhibiting MMPs may improve the effects of EGFR-targeted therapy.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents/pharmacology , Carcinoma, Squamous Cell/drug therapy , Fibroblasts/metabolism , Head and Neck Neoplasms/drug therapy , Matrix Metalloproteinase 1/metabolism , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Cetuximab , Coculture Techniques , Drug Resistance, Neoplasm , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Humans , RNA Interference , RNA, Neoplasm/genetics , Squamous Cell Carcinoma of Head and Neck , Tumor Cells, Cultured
13.
J Oral Pathol Med ; 40(10): 739-46, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21481002

ABSTRACT

BACKGROUND: Radiotherapy is the main therapy for head and neck squamous cell carcinoma (HNSCC); however, treatment resistance and local recurrence are significant problems, highlighting the need for predictive markers. In this study, we evaluated selected proteins, mutations, and single nucleotide polymorphisms (SNPs) involved in apoptosis, cell proliferation, and DNA repair alone or combined as predictive markers for radioresponse in 42 HNSCC cell lines. METHODS: The expression of epidermal growth factor receptor, survivin, Bax, Bcl-2, Bcl-X(L) , cyclooxygenase-2 (COX-2), and heat shock protein 70 was analyzed by ELISA. Furthermore, mutations and SNPs in the p53 gene as well as SNPs in the MDM2, XRCC1, and XRCC3 genes were analyzed for their relation to radioresponse. To enable the evaluation of the predictive value of several factors combined, each cell line was allocated points based on the number of negative points (NNP) system, and the NNP sum was correlated with radioresponse. RESULTS: Survivin was the only factor that alone was significantly correlated with the intrinsic radiosensitivity (IR; r = 0.36, P = 0.02). The combination of survivin, Bax, Bcl-2, Bcl-X(L) , COX-2, and the p53 Arg72Pro polymorphism was found to most strongly correlate with radioresponse (r = 0.553, P < 0.001). CONCLUSION: These data indicate that the IR of 42 HNSCC cell lines can be predicted by a panel of factors on both the protein and gene levels. Moreover, among the investigated factors, survivin was the most promising biomarker of radioresponse.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/radiotherapy , Genome, Human/genetics , Head and Neck Neoplasms/radiotherapy , Proteins/analysis , Radiation Tolerance/genetics , Apoptosis/genetics , Apoptosis Regulatory Proteins/analysis , Arginine/genetics , Biomarkers, Tumor/classification , Carcinoma, Squamous Cell/genetics , Cell Line, Tumor , Cell Proliferation , Cyclooxygenase 2/analysis , DNA Repair/genetics , DNA-Binding Proteins/genetics , ErbB Receptors/analysis , Female , HSP70 Heat-Shock Proteins/analysis , Head and Neck Neoplasms/genetics , Humans , Inhibitor of Apoptosis Proteins/analysis , Male , Neoplasm Proteins/analysis , Polymorphism, Single-Stranded Conformational/genetics , Proline/genetics , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-mdm2/genetics , Survivin , Tumor Suppressor Protein p53/genetics , X-ray Repair Cross Complementing Protein 1 , bcl-2-Associated X Protein/analysis , bcl-X Protein/analysis
14.
Apoptosis ; 15(5): 527-40, 2010 May.
Article in English | MEDLINE | ID: mdl-20077016

ABSTRACT

Lysosomal membrane permeabilization (LMP) occurs in response to a large variety of cell death stimuli causing release of cathepsins from the lysosomal lumen into the cytosol where they participate in apoptosis signaling. In some settings, apoptosis induction is dependent on an early release of cathepsins, while under other circumstances LMP occurs late in the cell death process and contributes to amplification of the death signal. The mechanism underlying LMP is still incompletely understood; however, a growing body of evidence suggests that LMP may be governed by several distinct mechanisms that are likely engaged in a death stimulus- and cell-type-dependent fashion. In this review, factors contributing to permeabilization of the lysosomal membrane including reactive oxygen species, lysosomal membrane lipid composition, proteases, p53, and Bcl-2 family proteins, are described. Potential mechanisms to safeguard lysosomal integrity and confer resistance to lysosome-dependent cell death are also discussed.


Subject(s)
Apoptosis/physiology , Intracellular Membranes/metabolism , Lysosomes , Animals , Cathepsins/genetics , Cathepsins/metabolism , Cholesterol/metabolism , Heat-Shock Proteins/genetics , Heat-Shock Proteins/metabolism , Lysosomes/metabolism , Lysosomes/ultrastructure , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/ultrastructure , Peptide Hydrolases/genetics , Peptide Hydrolases/metabolism , Permeability , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Signal Transduction/physiology , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
15.
Int J Mol Med ; 24(4): 549-56, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19724896

ABSTRACT

The present study was undertaken to evaluate the possibility of using a panel of proteins and single nucleotide polymorphisms (SNPs) involved in apoptosis, growth control, and DNA repair as predictive markers for cisplatin sensitivity. For this purpose the intrinsic cisplatin sensitivity (ICS) was determined in 39 cell lines derived from squamous cell carcinomas of the head and neck using a colony-forming assay. In these cell lines and in normal oral keratinocytes (NOK), the expression of epidermal growth factor receptor (EGFR), Hsp70, Bax, Bcl-2, Bcl-XL, survivin, and COX-2 was determined. Moreover, the p53, MDM2, FGFR4, XPC, XPD, XRCC1, and XRCC3 genes were analyzed for the presence of specific single nucleotide polymorphisms (SNPs). Pearson's correlation test showed that EGFR was the only protein that was significantly correlated to the ICS (r=0.388, p=0.015). The combination of EGFR, Hsp70, Bax, and Bcl-2 gave the strongest correlation (r=0.566, p

Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , DNA Repair/genetics , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/genetics , Apoptosis/genetics , Apoptosis/physiology , Cell Line, Tumor , Cells, Cultured , DNA-Binding Proteins/genetics , Head and Neck Neoplasms/metabolism , Humans , Polymorphism, Single Nucleotide , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-mdm2/genetics , Receptor, Fibroblast Growth Factor, Type 4/genetics , Tumor Suppressor Protein p53/genetics , X-ray Repair Cross Complementing Protein 1 , Xeroderma Pigmentosum Group D Protein/genetics , bcl-2-Associated X Protein/genetics
16.
Apoptosis ; 11(7): 1149-59, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16699952

ABSTRACT

Apoptosis is often associated with acidification of the cytosol and since loss of lysosomal proton gradient and release of lysosomal content are early events during apoptosis, we investigated if the lysosomal compartment could contribute to cytosolic acidification. After exposure of U937 cells to tumor necrosis factor-alpha, three populations; healthy, pre-apoptotic, and apoptotic cells, were identified by flow cytometry. These populations were investigated regarding intra-cellular pH and apoptosis-associated events. There was a drop in cytosolic pH from 7.2 +/- 0.1 in healthy cells to 6.8 +/- 0.1 in pre-apoptotic, caspase-negative cells. In apoptotic, caspase-positive cells, the pH was further decreased to 5.7 +/- 0.04. The cytosolic acidification was not affected by addition of specific inhibitors towards caspases or the mitochondrial F(0)F(1)-ATPase. In parallel to the cytosolic acidification, a rise in lysosomal pH from 4.3 +/- 0.3, in the healthy population, to 4.8 +/- 0.3 and 5.5 +/- 0.3 in the pre-apoptotic- and apoptotic populations, respectively, was detected. In addition, lysosomal membrane permeability increased as detected as release of cathepsin D from lysosomes to the cytosol in pre-apoptotic and apoptotic cells. We, thus, suggest that lysosomal proton release is the cause of the cytosolic acidification of U937 cells exposed to TNF-alpha.


Subject(s)
Apoptosis/drug effects , Cytosol/metabolism , Lysosomes/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Amides/pharmacology , Amino Acid Chloromethyl Ketones/pharmacology , Caspase 3 , Caspase 8 , Caspase Inhibitors , Caspases/metabolism , Cathepsin D/metabolism , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Size/drug effects , Cytosol/drug effects , Detergents/pharmacology , Enzyme Inhibitors/pharmacology , Humans , Hydrogen-Ion Concentration/drug effects , Intracellular Membranes/drug effects , Intracellular Membranes/physiology , Lysosomes/drug effects , Lysosomes/physiology , Mitochondrial Proton-Translocating ATPases/antagonists & inhibitors , Mitochondrial Proton-Translocating ATPases/metabolism , Oligomycins/pharmacology , Permeability/drug effects , Phosphatidylserines/metabolism , Protein Transport/drug effects , Protons , Serine/analogs & derivatives , Serine/pharmacology , U937 Cells
17.
Acta Otolaryngol ; 126(1): 70-81, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16308258

ABSTRACT

CONCLUSION: Intracellular cysteine cathepsins are pro-apoptotic factors involved in activation of caspases in two oral squamous cell carcinoma (SCC) cell lines. OBJECTIVE: To study the possible involvement of lysosomal cathepsins in oral SCC cell apoptosis. MATERIAL AND METHODS: Apoptosis was induced in the two human oral SCC cell lines UT-SCC-20A and UT-SCC-24A using naphthazarin or anti-Fas antibodies, and was studied by analysis of caspase activity and nuclear morphology. Involvement of lysosomal cathepsins was investigated using the cysteine cathepsin inhibitor z-FA-FMK and the cathepsin D inhibitor pepstatin A. The amounts of cellular and soluble Fas death receptor were determined by ELISA. RESULTS: Release of cathepsins from the lysosomes to the cytosol was observed early in apoptosis. Cysteine cathepsins were found to be involved in activation of caspases in response to treatment with naphthazarin or anti-Fas antibodies, but inhibition of cysteine cathepsin activity was not sufficient to prevent cell death. Moreover, inhibition of cysteine cathepsin activity resulted in increased expression of the Fas death receptor, suggesting involvement of extracellular cysteine cathepsins in death receptor shedding.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/physiology , Carcinoma, Squamous Cell/pathology , Cathepsins/physiology , Mouth Neoplasms/pathology , Naphthoquinones/pharmacology , fas Receptor/immunology , Apoptosis/drug effects , Apoptosis/immunology , Blotting, Western , Caspases/metabolism , Cathepsins/antagonists & inhibitors , Cathepsins/metabolism , Cell Line, Tumor , Cysteine Proteinase Inhibitors/pharmacology , Cytosol/enzymology , Dipeptides/pharmacology , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Humans , Intracellular Membranes/immunology , Ketones/pharmacology , Lysosomes/enzymology , Multivariate Analysis , Signal Transduction/physiology
18.
Int J Exp Pathol ; 86(5): 309-21, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16191103

ABSTRACT

Bcl-2 family members have long been known to control permeabilization of the mitochondrial membrane during apoptosis, but involvement of these proteins in lysosomal membrane permeabilization (LMP) was not considered until recently. The aim of this study was to investigate the mechanism underlying the release of lysosomal proteases to the cytosol seen during apoptosis, with special emphasis on the role of Bax. In human fibroblasts, exposed to the apoptosis-inducing drug staurosporine (STS), the release of the lysosomal protease cathepsin D to the cytosol was observed by immunocytochemistry. In response to STS treatment, there was a shift in Bax immunostaining from a diffuse to a punctate pattern. Confocal microscopy showed co-localization of Bax with both lysosomes and mitochondria in dying cells. Presence of Bax at the lysosomal membrane was confirmed by immuno-electron microscopy. Furthermore, when recombinant Bax was incubated with pure lysosomal fractions, Bax inserted into the lysosomal membrane and induced the release of lysosomal enzymes. Thus, we suggest that Bax is a mediator of LMP, possibly promoting the release of lysosomal enzymes to the cytosol during apoptosis.


Subject(s)
Intracellular Membranes/metabolism , Liver/ultrastructure , Lysosomes/metabolism , Animals , Apoptosis/physiology , Biological Transport , Blotting, Western , Cathepsin D/metabolism , Cell Line , Enzyme Inhibitors/pharmacology , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Immunohistochemistry/methods , Intracellular Membranes/chemistry , Intracellular Membranes/drug effects , Liver/metabolism , Microscopy, Confocal , Microscopy, Immunoelectron , Permeability/drug effects , Protein Kinase C/antagonists & inhibitors , Rats , Rats, Sprague-Dawley , Staurosporine/pharmacology
19.
Breast Cancer Res Treat ; 85(3): 229-38, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15111761

ABSTRACT

The lysosomal protease Cathepsin D (Cath D) is associated with increased invasiveness and metastasis in breast cancer. Both estrogen and tamoxifen have been reported to increase Cath D, which seems to contradict the efficacy of tamoxifen as an adjuvant for estrogen dependent breast cancer. Cath D is bioactive in the extracellular space but very little is known about hormonal regulation of secreted Cath D in vivo. In this study we used microdialysis to sample the extracellular fluid in estrogen receptor positive MCF-7 tumors in nude mice. We show that tamoxifen in combination with estradiol decreased secreted Cath D compared with estradiol treatment only in solid tumors in situ. Cell culture of MCF-7 cells revealed that estradiol and tamoxifen increased intracellular proteolytic activity of Cath D in a similar fashion whereas secretion of Cath D was increased by estradiol and inhibited by tamoxifen. Immunofluorescence showed that estradiol located Cath D to the cell surface, while tamoxifen accumulated Cath D to dense lysosomes in perinuclear regions. Moreover, tamoxifen increased the intracellular transporter of Cath D, the mannose 6-phosphate/IGF-II receptor (M6P/IGF2R). In contrast, estradiol decreased the levels of this receptor. Thus, secretion of Cath D is hormone dependent and may be mediated by altered expression of the M6P/IGF2R. Our results highlight the importance of measurements of proteins in all compartments where they are biological active and show that microdialysis is a viable technique for sampling of Cath D in vivo.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/drug therapy , Cathepsin D/metabolism , Receptor, IGF Type 2/metabolism , Tamoxifen/pharmacology , Analysis of Variance , Animals , Breast Neoplasms/metabolism , Cathepsin D/drug effects , Cell Line, Tumor , Estradiol/pharmacology , Female , In Vitro Techniques , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/metabolism , Mice , Mice, Nude , Microdialysis
SELECTION OF CITATIONS
SEARCH DETAIL
...